Aztiq ("Aztiq"), a healthcare investor led by Alvogen Founder and Chairman Róbert Wessman, and Innobic (Asia) Company Limited ("Innobic"),a life sciences subsidiary of Thailandindustrial group PTT, today announced the signing of a definitive agreement to acquire a 100% stake in Alvogen Emerging Market Holdings Limited ("AEMH") from its existing shareholders for$475 million. The aim of the alliance between Aztiq and Innobic and the transaction is to create a powerful pharmaceuticals enterprise with global resources, networks and reach.
Through the transaction, one of the largest in the sector this year, the consortium becomes the leading shareholder in the global oncology pharmaceutical company Lotus Pharmaceutical ("Lotus", TWSE ticker: 1795), and the sole shareholder in Alvogen Malta Holding Ltd., the owner of the fast-growing global business to business (B2B) pharmaceutical company Adalvo.
AEMH is currently owned by Alvogen Lux Holdings Sarl ("Alvogen"). Key shareholders in Alvogen include CVC Capital Partners and Temasek Holdings of Singapore, as well as Aztiq. Alvogen will remain a leading shareholder in the generic pharmaceutical company Alvogen US, including specialty pharma company Almatica, as well as the second largest shareholder in global biosimilars company Alvotech.